September 2026: British American Tobacco Faces Third UK Investor Claim Over Historical North Korea Disclosures
British American Tobacco (BAT) is facing a third UK shareholder lawsuit in the High Court of England and Wales over allegations that it failed to adequately disclose its historical North Korean operations and associated sanctions exposure to the market. The latest proceeding is being brought by institutional investors represented by international law firm McDermott Will & Schulte. Crucially, the lawsuit does not involve any new allegations of sanctions violations. Instead, it is a stock-drop securities claim arguing that BAT made misleading statements or dishonestly omitted and delayed crucial disclosures regarding its North Korean business, exposing shareholders to financial losses when regulatory risks eventually crystallized.
The action represents the third separate group of shareholders seeking compensation from BAT in London under Sections 90 and 90A of the Financial Services and Markets Act 2000 (FSMA):
– First Claim (February 2026): Filed by Fox Williams on behalf of nearly 130 international institutional investors.
– Second Claim (February 2026): Filed by Stewarts on behalf of institutional investors, including ReAssure (part of Standard Life) and Aberdeen.
– Third Claim (August 2026): Filed by McDermott Will & Schulte on behalf of another set of institutional investors.
The litigation stems from conduct dating back to 2007-2016, when BAT operated a North Korean joint venture through a Singapore subsidiary and third-party entities. In April 2023, BAT settled criminal and administrative investigations with U.S. authorities (DOJ and OFAC), paying approximately $635 million in penalties.
While a U.S. federal judge officially dismissed the criminal proceedings against BAT in May 2026 following full compliance with its three-year deferred prosecution agreement, the shareholder claims in the High Court indicate that the regulatory fallout has shifted into a persistent civil litigation exposure in the UK. BAT has acknowledged the ongoing proceedings in its H1 2026 report and stated its intention to vigorously defend against the claims.
August 2026: South Korean Court Rejects ₩68 billion Activist Lawsuit Against KT&G Directors
A South Korean court has dismissed a ₩68 billion ($49 million) shareholder derivative lawsuit brought by Singapore-based activist hedge fund Flashlight Capital Partners (FCP) against current and former board members of tobacco giant KT&G Corp. The ruling, delivered by the 11th Civil Division of the Daejeon District Court, marks a significant victory for KT&G management and sets a notable legal precedent regarding board discretion over treasury share transfers in South Korea.
The dispute originated from claims by Flashlight Capital Partners, an activist fund, against 18 current and former board members of KT&G. FCP alleged that over the 17 years following KT&G’s privatization in 2002, directors breached their fiduciary duties and acted negligently by donating or transferring company treasury shares worth an estimated ₩1 trillion ($706 million) to affiliated public foundations and employee welfare funds at zero or low cost. FCP contended that these transfers were part of an illegal effort to create friendly voting blocks holding over 12% of voting rights to entrench incumbent management and insulate the board from shareholder oversight.
The Daejeon District Court rejected FCP’s claims in their entirety, finding no evidence of fiduciary breach or illegal intent to entrench management. The court ruled that transferring treasury shares to corporate welfare funds and charitable foundations fell within the lawful scope of board authority, serving valid corporate purposes such as employee welfare enhancement and social responsibility, rather than acting as an unlawful defense mechanism.
Following the decision, KT&G welcomed the verdict, stating that the court affirmed the board acted lawfully and followed all necessary procedures in its treasury share management and corporate social contribution initiatives. Conversely, FCP expressed disappointment with the decision and confirmed its intention to appeal the ruling to a higher court. The lawsuit was part of a multi-year campaign by FCP against KT&G, which previously included proposals to spin off KT&G’s ginseng business for $1.4 billion and demands for aggressive treasury stock cancellations.
The case was closely watched across Asian capital markets as a landmark test of board accountability and shareholder activism in South Korea. Treasury share management remains a core friction point between activist investors and Korean corporate conglomerates, particularly as regulatory authorities push broader reforms aimed at curbing the ‘Korea Discount’ and protecting minority shareholder rights.
July 2026: Korean Court to Rule Next Month on Activist FCP’s Lawsuit Against KT&G Board
A South Korean court is set to deliver a high-stakes verdict next month on a major shareholder derivative lawsuit filed by Singapore-based activist fund Flashlight Capital Partners (FCP) against the KT&G board. The pending ruling marks a critical juncture in a multi-year legal and activist battle over corporate governance at the world’s fifth-largest tobacco manufacturer.
At the heart of the litigation – which FCP officially initiated in January 2025 – is the activist fund’s claim that KT&G’s current and former board members caused approximately ₩1 trillion ($750+ million) in damages to the company. FCP alleges that over a 17-year period following KT&G’s privatization in 2002, the board systematically transferred and donated treasury shares to affiliated public foundations and in-house employee welfare funds. According to FCP, these transfers were a calculated maneuver to build a friendly voting block. By distributing these treasury shares to allied foundations – historically led by former KT&G executive – these entities managed to accumulate voting rights exceeding 12%.
This collective stake is larger than that of KT&G’s largest official institutional shareholder. FCP argues that by using corporate treasury assets to secure “friendly” votes, the board effectively insulated itself from independent shareholder oversight and entrenched internal management. Because this is a shareholder derivative lawsuit, FCP is covering all legal expenses. If the court rules in FCP’s favor, any recovered damages will be paid back directly to KT&G rather than to the activist fund.
KT&G has strongly pushed back against FCP’s allegations, dismissing them as “unilateral and false.” The company maintains that all treasury share allocations were executed legally and in strict compliance with corporate procedures. According to KT&G, half of the shares in question were paid-in grants allocated to employee stock ownership associations, where workers contributed their own funds. Furthermore, KT&G defends the remaining transfers to public foundations as legitimate initiatives aimed at stabilizing workers’ livelihoods, improving internal employee welfare, and funding social contribution programs through stock dividends. The tobacco giant has expressed concerns that FCP’s public campaigns mischaracterize beneficial corporate social responsibility (CSR) initiatives and risk harming the company’s public image and the collective interests of its broader shareholder base.
The upcoming verdict represents a watershed moment for shareholder activism in South Korea, where the misuse of treasury shares has long been a flashpoint for critics of the country’s corporate governance standards. FCP has waged a high-profile, three-year campaign against KT&G. The activist fund has previously pushed for the spin-off of KT&G’s ailing ginseng business, demanded transparency on overseas distribution deals with Philip Morris International, and successfully placed an independent director on KT&G’s board in 2024.
Though FCP trimmed more than half of its stake in KT&G in early 2026 to lock in investment gains, it has kept its legal focus trained on the company’s board. The court’s decision next month is highly anticipated by international and domestic investors alike, as it could set a major legal precedent regarding the fiduciary duties of board directors and the regulation of treasury shares in South Korea.
July 2026: British American Tobacco Faces Second Shareholder Claim in London Over Secret North Korea Operations
British American Tobacco (BAT) is facing a growing wave of shareholder litigation in the U.K., as a second group of investors has filed a major claim in the London High Court. The lawsuit accuses the tobacco giant of failing to provide timely and accurate market disclosures regarding its historical business operations in North Korea, which ultimately triggered massive U.S. regulatory penalties.
The new claim is being brought on behalf of institutional investors who allege that BAT misled the investing public for more than a decade. According to the claimants, BAT publicly claimed in 2007 that it was exiting the North Korean market due to mounting international pressure. In reality, the company allegedly spent the next ten years utilizing a sophisticated network of front companies and a Singaporean proxy subsidiary to continue selling tobacco products to Pyongyang, routing hundreds of millions of dollars through the U.S. banking system. Investors argue that by concealing these systemic sanctions violations between 2007 and 2023, BAT artificially inflated its share price. When the true extent of the corporate misconduct was finally laid bare, shareholders suffered substantial losses due to resulting stock volatility.
The escalating civil litigation stems from a landmark April 2023 settlement with United States authorities. The U.S. Department of Justice (DOJ) and the Treasury’s Office of Foreign Assets Control (OFAC) accused BAT of bank fraud and massive sanctions evasion. U.S. officials noted that the profits generated from BAT’s clandestine operations directly helped fund North Korea’s weapons of mass destruction programs.
To resolve the criminal charges, BAT entered into a deferred prosecution agreement (DPA) and agreed to pay a combined $629 million in penalties and fines – marking the largest-ever U.S. sanctions penalty involving North Korea. A U.S. federal judge officially dismissed the underlying criminal case after BAT fully complied with the terms of the multi-year DPA and paid the required penalties.
The new case marks the second major legal front BAT has had to defend in the U.K. regarding the fallout from its North Korean operations. The company was first hit with investor litigation in the London High Court when a group of more than 100 current and former shareholders filed a parallel lawsuit.
Like the second group, the initial claimants allege that BAT breached its statutory disclosure duties under the U.K.’s Financial Services and Markets Act by withholding material information from the stock market about its sanctions exposure. With multiple claimant groups now seeking redress, the twin High Court actions spotlight the intensifying financial and transparency risks multinational corporations face in London over hidden geopolitical misconduct.
March 2026: British American Tobacco Faces Shareholder Lawsuit in UK Over North Korea Sanctions Case
More than 100 current and former shareholders have filed a lawsuit against British American Tobacco (BAT) in London’s High Court, alleging the company failed to properly disclose breaches of U.S. sanctions related to its business activities in North Korea. The claim argues that BAT did not adequately inform the market about the extent of these activities between 2007 and 2023, potentially misleading investors about the legal and regulatory risks facing the company.
The legal action follows BAT’s 2023 settlement with U.S. authorities, in which the company agreed to pay more than $635 million after a subsidiary admitted to conspiring to violate U.S. sanctions and commit bank fraud by selling tobacco products to North Korea between 2007 and 2017. Lawyers representing the shareholders argue that the company should have disclosed these issues earlier to the market. The total value of the claim has not been disclosed, and BAT has not yet publicly commented on the lawsuit. A separate case against the company was reportedly filed in the High Court on the same day by another group of claimants.
December 2023: US Appeals Court Hands Philip Morris Win in IQOS Securities Fraud Suit
Philip Morris International (PMI) has secured a final legal victory in a high-stakes shareholder class action after a U.S. federal appeals court affirmed the dismissal of all securities fraud claims against the tobacco giant and its executives. The decision, handed down by the U.S. Court of Appeals for the Second Circuit, upholds a September 2021 district court ruling that rejected allegations from lead investors claiming PMI made false and misleading statements about its heated tobacco flagship, IQOS.
The putative class action – led by institutional investors represented by Pomerantz LLP and Robbins Geller Rudman & Dowd LLP – accused PMI of misleading the public on two main fronts: the scientific integrity of its IQOS clinical trials submitted to the U.S. Food and Drug Administration (FDA), and commercial growth projections in the Japanese market.
In affirming the suit’s dismissal, the Second Circuit established key determinations regarding corporate statements and scientific data:
– Statements of Opinion and Puffery: Characterizations by PMI executives describing IQOS research as “rigorous,” “the best science,” or “very advanced” were ruled as non-actionable puffery and subjective expressions of opinion rather than verifiable representations of objective fact.
– FDA Authorization Validates Scientific Claims: The court concluded that PMI’s interpretation of its scientific data was inherently reasonable as a matter of law, pointing to the FDA’s subsequent Modified Risk Tobacco Product (MRTP) authorization as concrete validation of the company’s research conclusions.
– Allowable Forward-Looking Projections: Optimistic growth forecasts and comments regarding IQOS performance in Japan fell within the legal protections for forward-looking statements, with plaintiffs failing to establish material falsity.
The outcome marks a critical legal precedent for life sciences and harm-reduction product manufacturers navigating public disclosures surrounding regulatory submissions. By holding that FDA endorsement demonstrates the inherent reasonableness of a company’s data interpretation, the ruling raises the legal bar for shareholders attempting to bring fraud claims based on disputed scientific protocols.
The decision resolves a long-standing threat to PMI’s smoke-free transition narrative at a time when major securities litigation firms, including co-lead counsel Pomerantz LLP, continue to target rival tobacco manufacturers over regulatory and compliance disclosures.
December 2023: Law Firms Launch Fraud Probes into British American Tobacco Following Historic £25B U.S. Write-Down
A wave of shareholder class-action investigations has hit British American Tobacco p.l.c. (BAT) following the company’s disclosure of a massive £25 billion ($31.5 billion) impairment charge on its U.S. cigarette portfolio, an announcement that triggered a steep sell-off in the tobacco giant’s shares. Over a dozen prominent investor rights and securities litigation firms—including Pomerantz LLP, the Law Offices of Frank R. Cruz, and Glancy Prongay & Murray LLP—announced probes into whether BAT and its executive team violated federal securities laws by understating the impairment risks associated with its flagship American combustible brands.
The legal scrutiny follows BAT’s December 6 interim business update, in which the London-headquartered firm revealed one of the largest corporate write-downs in consumer goods history. BAT announced it would take a non-cash adjusting impairment charge of approximately £25 billion to reassess the carrying value and useful economic lives of key U.S. combustible brands over a finite 30-year horizon.
Market reaction was immediate: BAT’s American Depositary Receipts (ADRs) plummeted 8.5% (down $2.68) on December 6 to close at $28.86 per share, hitting multi-year lows. The write-down largely stems from assets acquired in BAT’s $49 billion takeover of Reynolds American in 2017, including major U.S. brands Newport, Camel, Pall Mall, and Natural American Spirit.
Law firms leading the inquiries are investigating whether BAT misled market participants regarding the economic health and long-term valuation of its U.S. business. Specifically, plaintiffs’ attorneys are assessing whether the company:
– Materially understated the likelihood and timeline of a massive impairment to its U.S. premium cigarette brands.
– Failed to timely inform investors of the compounding impacts of macroeconomic pressures, inflation-driven consumer down-trading to low-cost alternatives, and regulatory headwinds on U.S. smokeable volume.
– Provided overly optimistic projections regarding the financial durability of its legacy combustible portfolio.
Defending the strategy, BAT Chief Executive Officer (CEO) characterized the decision as “accounting catching up with reality.” Speaking during the update, he noted that while traditional cigarettes will not disappear overnight, maintaining an indefinite balance sheet valuation for brands facing structural, long-term industry decline was no longer justifiable. The company emphasized that it is pivoting towards its “Build a Smokeless World” vision, aiming to derive 50% of group revenue from non-combustible products – such as its Vuse e-cigarettes and Velo nicotine pouches – by 2035.
However, legal analysts note that the suddenness and sheer scale of the write-down leave the board vulnerable to formal shareholder class actions, with law firms actively seeking affected investors to serve as lead plaintiffs in upcoming federal complaints.
